Taro Pharmaceutical Industries Ltd. (TARO) Stock Competitors & Peer Comparison

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TAK has a market cap of 49.7B. Regarding current trading prices, TARO is priced at $42.98, while TAK trades at $15.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TAK's P/E ratio is 41.36. In terms of profitability, TARO's ROE is +0.03%, compared to TAK's ROE of +0.03%. Regarding short-term risk, TARO is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check TAK's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, HLN has a market cap of 40.5B. Regarding current trading prices, TARO is priced at $42.98, while HLN trades at $9.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas HLN's P/E ratio is 18.24. In terms of profitability, TARO's ROE is +0.03%, compared to HLN's ROE of +0.17%. Regarding short-term risk, TARO is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check HLN's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TEVA has a market cap of 40.1B. Regarding current trading prices, TARO is priced at $42.98, while TEVA trades at $33.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TEVA's P/E ratio is 25.70. In terms of profitability, TARO's ROE is +0.03%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, TARO is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check TEVA's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, VTRS has a market cap of 18.9B. Regarding current trading prices, TARO is priced at $42.98, while VTRS trades at $15.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas VTRS's P/E ratio is -54.00. In terms of profitability, TARO's ROE is +0.03%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, TARO is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check VTRS's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TARO is priced at $42.98, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TARO's ROE is +0.03%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TARO is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check ITCI's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ELAN has a market cap of 12.2B. Regarding current trading prices, TARO is priced at $42.98, while ELAN trades at $23.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ELAN's P/E ratio is -48.98. In terms of profitability, TARO's ROE is +0.03%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, TARO is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ELAN's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TARO is priced at $42.98, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TARO's ROE is +0.03%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TARO and CTLT have similar daily volatility (0.09).Check CTLT's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, RDY has a market cap of 11.1B. Regarding current trading prices, TARO is priced at $42.98, while RDY trades at $13.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas RDY's P/E ratio is 25.23. In terms of profitability, TARO's ROE is +0.03%, compared to RDY's ROE of +0.12%. Regarding short-term risk, TARO is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check RDY's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, RGC has a market cap of 10B. Regarding current trading prices, TARO is priced at $42.98, while RGC trades at $20.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas RGC's P/E ratio is -2031.00. In terms of profitability, TARO's ROE is +0.03%, compared to RGC's ROE of -2.32%. Regarding short-term risk, TARO is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check RGC's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, TARO is priced at $42.98, while LNTH trades at $102.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas LNTH's P/E ratio is 23.86. In terms of profitability, TARO's ROE is +0.03%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, TARO is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check LNTH's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, TARO is priced at $42.98, while INDV trades at $38.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas INDV's P/E ratio is 19.62. In terms of profitability, TARO's ROE is +0.03%, compared to INDV's ROE of -1.42%. Regarding short-term risk, TARO is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check INDV's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AMRX has a market cap of 4.7B. Regarding current trading prices, TARO is priced at $42.98, while AMRX trades at $15.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AMRX's P/E ratio is 39.70. In terms of profitability, TARO's ROE is +0.03%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, TARO is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check AMRX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, TARO is priced at $42.98, while SUPN trades at $45.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SUPN's P/E ratio is -89.53. In terms of profitability, TARO's ROE is +0.03%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, TARO is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check SUPN's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TARO is priced at $42.98, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TARO's ROE is +0.03%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TARO is less volatile compared to DCPH. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check DCPH's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TARO is priced at $42.98, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TARO's ROE is +0.03%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, TARO is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check AVDL's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, BHC has a market cap of 1.9B. Regarding current trading prices, TARO is priced at $42.98, while BHC trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas BHC's P/E ratio is -1.60. In terms of profitability, TARO's ROE is +0.03%, compared to BHC's ROE of +1.21%. Regarding short-term risk, TARO is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check BHC's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TARO is priced at $42.98, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TARO's ROE is +0.03%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, TARO is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check EMBCV's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, HCM has a market cap of 1.9B. Regarding current trading prices, TARO is priced at $42.98, while HCM trades at $10.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas HCM's P/E ratio is 4.01. In terms of profitability, TARO's ROE is +0.03%, compared to HCM's ROE of +0.41%. Regarding short-term risk, TARO is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check HCM's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, TARO is priced at $42.98, while ANIP trades at $81.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ANIP's P/E ratio is 20.77. In terms of profitability, TARO's ROE is +0.03%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, TARO is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ANIP's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TARO is priced at $42.98, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TARO's ROE is +0.03%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, TARO is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check DVAX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PRGO has a market cap of 1.5B. Regarding current trading prices, TARO is priced at $42.98, while PRGO trades at $11.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PRGO's P/E ratio is -0.86. In terms of profitability, TARO's ROE is +0.03%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, TARO is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check PRGO's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ALVOW has a market cap of 1.4B. Regarding current trading prices, TARO is priced at $42.98, while ALVOW trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ALVOW's P/E ratio is N/A. In terms of profitability, TARO's ROE is +0.03%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, TARO is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ALVOW's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, TARO is priced at $42.98, while PAHC trades at $31.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PAHC's P/E ratio is 14.01. In terms of profitability, TARO's ROE is +0.03%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, TARO is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check PAHC's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, TARO is priced at $42.98, while ALVO trades at $4.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ALVO's P/E ratio is 41.60. In terms of profitability, TARO's ROE is +0.03%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, TARO is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ALVO's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, TARO is priced at $42.98, while HROW trades at $37.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas HROW's P/E ratio is -88.05. In terms of profitability, TARO's ROE is +0.03%, compared to HROW's ROE of -0.34%. Regarding short-term risk, TARO is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check HROW's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, COLL has a market cap of 1.1B. Regarding current trading prices, TARO is priced at $42.98, while COLL trades at $34.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas COLL's P/E ratio is 16.70. In terms of profitability, TARO's ROE is +0.03%, compared to COLL's ROE of +0.27%. Regarding short-term risk, TARO is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check COLL's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CRON has a market cap of 1B. Regarding current trading prices, TARO is priced at $42.98, while CRON trades at $2.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CRON's P/E ratio is -139.50. In terms of profitability, TARO's ROE is +0.03%, compared to CRON's ROE of -0.00%. Regarding short-term risk, TARO is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check CRON's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EVO has a market cap of 976.8M. Regarding current trading prices, TARO is priced at $42.98, while EVO trades at $2.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EVO's P/E ratio is -4.37. In terms of profitability, TARO's ROE is +0.03%, compared to EVO's ROE of -0.24%. Regarding short-term risk, TARO is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check EVO's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TARO is priced at $42.98, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TARO's ROE is +0.03%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TARO is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check PETQ's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PCRX has a market cap of 913M. Regarding current trading prices, TARO is priced at $42.98, while PCRX trades at $23.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PCRX's P/E ratio is 178.54. In terms of profitability, TARO's ROE is +0.03%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, TARO is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check PCRX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AMPH has a market cap of 888.9M. Regarding current trading prices, TARO is priced at $42.98, while AMPH trades at $20.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AMPH's P/E ratio is 12.14. In terms of profitability, TARO's ROE is +0.03%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, TARO is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check AMPH's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TLRY has a market cap of 618.4M. Regarding current trading prices, TARO is priced at $42.98, while TLRY trades at $5.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TLRY's P/E ratio is -0.35. In terms of profitability, TARO's ROE is +0.03%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, TARO is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check TLRY's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TARO is priced at $42.98, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TARO's ROE is +0.03%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TARO is less volatile compared to BDSI. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check BDSI's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, IRWD has a market cap of 530.1M. Regarding current trading prices, TARO is priced at $42.98, while IRWD trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas IRWD's P/E ratio is 5.19. In terms of profitability, TARO's ROE is +0.03%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, TARO is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check IRWD's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EOLS has a market cap of 441.2M. Regarding current trading prices, TARO is priced at $42.98, while EOLS trades at $6.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EOLS's P/E ratio is -10.15. In terms of profitability, TARO's ROE is +0.03%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, TARO is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check EOLS's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CGC has a market cap of 434.4M. Regarding current trading prices, TARO is priced at $42.98, while CGC trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CGC's P/E ratio is -0.76. In terms of profitability, TARO's ROE is +0.03%, compared to CGC's ROE of -0.51%. Regarding short-term risk, TARO is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check CGC's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, KMDA has a market cap of 417.6M. Regarding current trading prices, TARO is priced at $42.98, while KMDA trades at $7.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas KMDA's P/E ratio is 20.69. In terms of profitability, TARO's ROE is +0.03%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TARO is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check KMDA's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AQST has a market cap of 396.2M. Regarding current trading prices, TARO is priced at $42.98, while AQST trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AQST's P/E ratio is -6.54. In terms of profitability, TARO's ROE is +0.03%, compared to AQST's ROE of +1.91%. Regarding short-term risk, TARO is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check AQST's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SNDL has a market cap of 379.8M. Regarding current trading prices, TARO is priced at $42.98, while SNDL trades at $1.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SNDL's P/E ratio is -48.67. In terms of profitability, TARO's ROE is +0.03%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, TARO is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check SNDL's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ORGO has a market cap of 319.1M. Regarding current trading prices, TARO is priced at $42.98, while ORGO trades at $2.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ORGO's P/E ratio is -20.67. In terms of profitability, TARO's ROE is +0.03%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, TARO is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ORGO's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SIGA has a market cap of 314.9M. Regarding current trading prices, TARO is priced at $42.98, while SIGA trades at $4.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SIGA's P/E ratio is 15.68. In terms of profitability, TARO's ROE is +0.03%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, TARO is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check SIGA's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TARO is priced at $42.98, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TARO's ROE is +0.03%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TARO is less volatile compared to ALIM. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ALIM's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TARO is priced at $42.98, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TARO's ROE is +0.03%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, TARO is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check LNDC's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TKNO has a market cap of 239.1M. Regarding current trading prices, TARO is priced at $42.98, while TKNO trades at $4.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TKNO's P/E ratio is -13.94. In terms of profitability, TARO's ROE is +0.03%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, TARO is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check TKNO's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TARO is priced at $42.98, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TARO's ROE is +0.03%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, TARO is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check TYHT's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, LFCR has a market cap of 212.3M. Regarding current trading prices, TARO is priced at $42.98, while LFCR trades at $5.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas LFCR's P/E ratio is -4.46. In terms of profitability, TARO's ROE is +0.03%, compared to LFCR's ROE of -1.76%. Regarding short-term risk, TARO is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check LFCR's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ACB has a market cap of 199.8M. Regarding current trading prices, TARO is priced at $42.98, while ACB trades at $3.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ACB's P/E ratio is -3.16. In terms of profitability, TARO's ROE is +0.03%, compared to ACB's ROE of -0.08%. Regarding short-term risk, TARO is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ACB's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EMBC has a market cap of 196.4M. Regarding current trading prices, TARO is priced at $42.98, while EMBC trades at $3.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EMBC's P/E ratio is 1.75. In terms of profitability, TARO's ROE is +0.03%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, TARO is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check EMBC's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TARO is priced at $42.98, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas REPH's P/E ratio is -8.04. In terms of profitability, TARO's ROE is +0.03%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TARO is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check REPH's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, DERM has a market cap of 170.1M. Regarding current trading prices, TARO is priced at $42.98, while DERM trades at $6.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas DERM's P/E ratio is -16.70. In terms of profitability, TARO's ROE is +0.03%, compared to DERM's ROE of -0.36%. Regarding short-term risk, TARO is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check DERM's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TARO is priced at $42.98, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas THTX's P/E ratio is -17.84. In terms of profitability, TARO's ROE is +0.03%, compared to THTX's ROE of +0.17%. Regarding short-term risk, TARO is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check THTX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, OGI has a market cap of 152M. Regarding current trading prices, TARO is priced at $42.98, while OGI trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas OGI's P/E ratio is -7.20. In terms of profitability, TARO's ROE is +0.03%, compared to OGI's ROE of -0.07%. Regarding short-term risk, TARO is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check OGI's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ASRT has a market cap of 151.6M. Regarding current trading prices, TARO is priced at $42.98, while ASRT trades at $23.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ASRT's P/E ratio is -4.23. In terms of profitability, TARO's ROE is +0.03%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TARO and ASRT have similar daily volatility (0.09).Check ASRT's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CRDL has a market cap of 120.8M. Regarding current trading prices, TARO is priced at $42.98, while CRDL trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CRDL's P/E ratio is -3.86. In terms of profitability, TARO's ROE is +0.03%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, TARO is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check CRDL's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TARO is priced at $42.98, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TARO's ROE is +0.03%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TARO is less volatile compared to SCTL. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check SCTL's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TARO is priced at $42.98, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PROC's P/E ratio is 1.53. In terms of profitability, TARO's ROE is +0.03%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TARO is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check PROC's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TARO is priced at $42.98, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TARO's ROE is +0.03%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, TARO is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check OPTN's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TARO is priced at $42.98, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TARO's ROE is +0.03%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, TARO is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ZOM's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TARO is priced at $42.98, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TARO's ROE is +0.03%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, TARO is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check GRVI's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CPIX has a market cap of 85.7M. Regarding current trading prices, TARO is priced at $42.98, while CPIX trades at $5.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CPIX's P/E ratio is -11.67. In terms of profitability, TARO's ROE is +0.03%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, TARO is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check CPIX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TARO is priced at $42.98, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TARO's ROE is +0.03%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TARO is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ZYNE's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, BGM has a market cap of 69.3M. Regarding current trading prices, TARO is priced at $42.98, while BGM trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas BGM's P/E ratio is -1.19. In terms of profitability, TARO's ROE is +0.03%, compared to BGM's ROE of -0.03%. Regarding short-term risk, TARO is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check BGM's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TARO is priced at $42.98, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TARO's ROE is +0.03%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TARO is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check SSIC's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TARO is priced at $42.98, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TARO's ROE is +0.03%, compared to VLNS's ROE of N/A. Regarding short-term risk, TARO is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check VLNS's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TARO is priced at $42.98, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TARO's ROE is +0.03%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, TARO is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check DRRX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, INCR has a market cap of 52.7M. Regarding current trading prices, TARO is priced at $42.98, while INCR trades at $0.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas INCR's P/E ratio is -4.19. In terms of profitability, TARO's ROE is +0.03%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TARO is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check INCR's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TARO is priced at $42.98, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TARO's ROE is +0.03%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, TARO is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check JUPW's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ZYBT has a market cap of 42.2M. Regarding current trading prices, TARO is priced at $42.98, while ZYBT trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ZYBT's P/E ratio is -4.05. In terms of profitability, TARO's ROE is +0.03%, compared to ZYBT's ROE of -0.26%. Regarding short-term risk, TARO is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ZYBT's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, IXHL has a market cap of 42.1M. Regarding current trading prices, TARO is priced at $42.98, while IXHL trades at $3.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas IXHL's P/E ratio is -0.22. In terms of profitability, TARO's ROE is +0.03%, compared to IXHL's ROE of -1.23%. Regarding short-term risk, TARO is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check IXHL's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TARO is priced at $42.98, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas QLI's P/E ratio is -4.92. In terms of profitability, TARO's ROE is +0.03%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TARO is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check QLI's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TARO is priced at $42.98, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TARO's ROE is +0.03%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TARO is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check HEXO's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SCYX has a market cap of 27.4M. Regarding current trading prices, TARO is priced at $42.98, while SCYX trades at $4.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SCYX's P/E ratio is -1.14. In terms of profitability, TARO's ROE is +0.03%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, TARO is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check SCYX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, RMTI has a market cap of 27.1M. Regarding current trading prices, TARO is priced at $42.98, while RMTI trades at $0.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas RMTI's P/E ratio is -4.57. In terms of profitability, TARO's ROE is +0.03%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, TARO is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check RMTI's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TARO is priced at $42.98, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TARO's ROE is +0.03%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TARO is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check CYTH's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TXMD has a market cap of 21.8M. Regarding current trading prices, TARO is priced at $42.98, while TXMD trades at $1.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TXMD's P/E ratio is 188.00. In terms of profitability, TARO's ROE is +0.03%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, TARO is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check TXMD's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TARO is priced at $42.98, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TARO's ROE is +0.03%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, TARO is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check EVOK's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AYTU has a market cap of 18.6M. Regarding current trading prices, TARO is priced at $42.98, while AYTU trades at $2.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AYTU's P/E ratio is -0.49. In terms of profitability, TARO's ROE is +0.03%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, TARO is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check AYTU's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, QNTM has a market cap of 17.5M. Regarding current trading prices, TARO is priced at $42.98, while QNTM trades at $4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas QNTM's P/E ratio is -0.50. In terms of profitability, TARO's ROE is +0.03%, compared to QNTM's ROE of -6.22%. Regarding short-term risk, TARO is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check QNTM's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TLPH has a market cap of 16.7M. Regarding current trading prices, TARO is priced at $42.98, while TLPH trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TLPH's P/E ratio is -2.91. In terms of profitability, TARO's ROE is +0.03%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, TARO is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check TLPH's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, OPTH has a market cap of 15.7M. Regarding current trading prices, TARO is priced at $42.98, while OPTH trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas OPTH's P/E ratio is -3.95. In terms of profitability, TARO's ROE is +0.03%, compared to OPTH's ROE of -0.57%. Regarding short-term risk, TARO is less volatile compared to OPTH. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check OPTH's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TARO is priced at $42.98, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TARO's ROE is +0.03%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, TARO is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ACRX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, COSM has a market cap of 13.4M. Regarding current trading prices, TARO is priced at $42.98, while COSM trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas COSM's P/E ratio is -0.34. In terms of profitability, TARO's ROE is +0.03%, compared to COSM's ROE of -0.96%. Regarding short-term risk, TARO is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check COSM's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, BFRI has a market cap of 10.8M. Regarding current trading prices, TARO is priced at $42.98, while BFRI trades at $0.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas BFRI's P/E ratio is -0.86. In terms of profitability, TARO's ROE is +0.03%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, TARO is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check BFRI's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TARO is priced at $42.98, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TARO's ROE is +0.03%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TARO is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check AGRX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TARO is priced at $42.98, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TARO's ROE is +0.03%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, TARO is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check NLTX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EGRX has a market cap of 7.9M. Regarding current trading prices, TARO is priced at $42.98, while EGRX trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EGRX's P/E ratio is 8.57. In terms of profitability, TARO's ROE is +0.03%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, TARO is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check EGRX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TARO is priced at $42.98, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas LCI's P/E ratio is -0.04. In terms of profitability, TARO's ROE is +0.03%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TARO is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check LCI's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, YCBD has a market cap of 7.4M. Regarding current trading prices, TARO is priced at $42.98, while YCBD trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas YCBD's P/E ratio is 0.28. In terms of profitability, TARO's ROE is +0.03%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TARO is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check YCBD's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, TARO is priced at $42.98, while BGXX trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas BGXX's P/E ratio is -0.76. In terms of profitability, TARO's ROE is +0.03%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, TARO is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check BGXX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TARO is priced at $42.98, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TARO's ROE is +0.03%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TARO is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check ADMP's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TARO is priced at $42.98, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas MNK's P/E ratio is -0.44. In terms of profitability, TARO's ROE is +0.03%, compared to MNK's ROE of -0.26%. Regarding short-term risk, TARO is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check MNK's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, GELS has a market cap of 4.5M. Regarding current trading prices, TARO is priced at $42.98, while GELS trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas GELS's P/E ratio is -0.96. In terms of profitability, TARO's ROE is +0.03%, compared to GELS's ROE of -0.43%. Regarding short-term risk, TARO is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check GELS's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TARO is priced at $42.98, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TARO's ROE is +0.03%, compared to FLGC's ROE of -0.08%. Regarding short-term risk, TARO is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check FLGC's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, TARO is priced at $42.98, while GHSI trades at $3.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas GHSI's P/E ratio is -0.79. In terms of profitability, TARO's ROE is +0.03%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, TARO is more volatile compared to GHSI. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check GHSI's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TARO is priced at $42.98, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TARO's ROE is +0.03%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TARO is less volatile compared to PLXP. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check PLXP's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, RDHL has a market cap of 2.5M. Regarding current trading prices, TARO is priced at $42.98, while RDHL trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas RDHL's P/E ratio is N/A. In terms of profitability, TARO's ROE is +0.03%, compared to RDHL's ROE of +2.91%. Regarding short-term risk, TARO is less volatile compared to RDHL. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check RDHL's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TARO is priced at $42.98, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TARO's ROE is +0.03%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TARO is more volatile compared to ATNX. This indicates potentially higher risk in terms of short-term price fluctuations for TARO.Check ATNX's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CPHI has a market cap of 2.3M. Regarding current trading prices, TARO is priced at $42.98, while CPHI trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CPHI's P/E ratio is -1.33. In terms of profitability, TARO's ROE is +0.03%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, TARO is less volatile compared to CPHI. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check CPHI's competition here

TARO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, UPC has a market cap of 2M. Regarding current trading prices, TARO is priced at $42.98, while UPC trades at $3.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas UPC's P/E ratio is -0.44. In terms of profitability, TARO's ROE is +0.03%, compared to UPC's ROE of -0.07%. Regarding short-term risk, TARO is less volatile compared to UPC. This indicates potentially lower risk in terms of short-term price fluctuations for TARO.Check UPC's competition here